$-0.05 EPS Expected for Synthetic Biologics Inc (SYN)

October 29, 2017 – By Dolores Ford

Analysts await Synthetic Biologics Inc (NYSEAMERICAN:SYN) to report earnings on November, 7. They expect $-0.05 EPS, up 44.44 % or $0.04 from last year’s $-0.09 per share. After $-0.03 actual EPS reported by Synthetic Biologics Inc for the previous quarter, Wall Street now forecasts 66.67 % negative EPS growth. It closed at $0.83 lastly. It is up 76.19% since October 30, 2016 and is downtrending. It has underperformed by 92.89% the S&P500.

Synthetic Biologics, Inc. is a clinical-stage company. The company has market cap of $106.45 million. The Firm is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. It currently has negative earnings. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation , and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection (CDI) and antibiotic-associated diarrhea (AAD).

Another recent and important Synthetic Biologics Inc (NYSEAMERICAN:SYN) news was published by Prnewswire.com which published an article titled: “Synthetic Biologics to Report Third Quarter 2017 Operational Highlights and …” on October 25, 2017.